Global search

Find data and evidence

Type at least 2 characters. Use arrow keys to review and Enter to open.

Peer reviewedOpen accessGastroenteritis

Effectiveness of Monovalent Rotavirus Vaccine Against Hospitalization With Acute Rotavirus Gastroenteritis in Kenyan Children

Clinical Infectious Diseases·

Sammy Khagayi, Richard Omore, Grieven P Otieno, Billy Ogwel, John B Ochieng, Jane Juma, Evans Apondi, Godfrey Bigogo, Clayton Onyango, Mwanajuma Ngama, Regina Njeru, Betty E Owor, Mike J Mwanga, Yaw Addo, Collins Tabu, Anyangu Amwayi, Jason M Mwenda, Jacqueline E Tate, Umesh D Parashar, Robert F Breiman, D James Nokes, Jennifer R Verani

DOI
10.1093/cid/ciz664
PMID
31326980
PMCID
PMC7245145
OpenAlex
W2963382129
Study type
Journal article
Publisher
Oxford University Press (OUP)
Article type
journal-article
Integrity
current

Why this research matters now

Findings support the protective benefit of RV1 within the Kenyan immunization program and indicate that efforts to improve vaccine uptake and nutritional status may be important to maximize impact.

01

Structured evidence summary

Research question

The study assessed monovalent rotavirus vaccine (RV1) effectiveness against rotavirus-associated hospitalization among Kenyan children following vaccine introduction.

Study design

Multi-site hospital-based surveillance using a case-control design (rotavirus-positive cases vs. rotavirus-negative controls) with multivariable logistic regression to derive vaccine effectiveness from adjusted odds ratios.

Population and setting

Children age-eligible for at least one RV1 dose, enrolled between July 2014 and December 2017 at three Kenyan hospitals under acute gastroenteritis surveillance.

Main findings

Among 677 eligible children, 110 (16%) were rotavirus positive. Overall two-dose RV1 effectiveness against rotavirus-associated hospitalization was 64% (95% CI, 35%–80%), and the abstract reports that effectiveness persisted beyond infancy, though the age-specific estimate is truncated. The authors note that malnutrition appears to diminish vaccine effectiveness.

Public-health relevance

Findings support the protective benefit of RV1 within the Kenyan immunization program and indicate that efforts to improve vaccine uptake and nutritional status may be important to maximize impact.

Important limitations

The abstract does not enumerate explicit study limitations. This summary is limited to the supplied single-article abstract/metadata and requires the original paper for decision-grade interpretation.

GIDS interpretation

Classified under gastroenteritis surveillance, vaccination, and vaccine effectiveness for Kenya. This study could contribute to contextual evidence for rotavirus vaccine performance in sub-Saharan Africa but does not by itself confirm any active surveillance signal.

02

Related GIDS surveillance

Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.

03

Evidence relationships

This article has 11 auditable classifier relationships to diseases, places, topics, and study design.

about diseaseaddresses topicaddresses topicaddresses topicevaluates interventionhas pathogen typestudied instudied population settingstudies populationstudies populationuses study design